The Future Contribution of China to Medicines Development and Human Subjects Protections

ISSN： 1364-9027

Source： International Journal of Pharmaceutical Medicine, Vol.20, Iss.6, 2006-01, pp. : 353-354

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Human Subjects Protections in Clinical Drug Trials in China: A Focus on the Institute Level

By Xu Jiaqi

International Journal of Pharmaceutical Medicine, Vol. 20, Iss. 6, 2006-01 ,pp. : 367-372

Adis International

Access to resources Recommend Favorite

Report of a Workshop on `Human Subjects Protections − Developing Ethical Review Management': 20−21 February 2006; Shanghai, China

By Liu Haitao Heidi

International Journal of Pharmaceutical Medicine, Vol. 20, Iss. 6, 2006-01 ,pp. : 379-382

Adis International

Access to resources Recommend Favorite

China as a Growing Research Base for Innovation in Medicines Development

By Humphries Michael

International Journal of Pharmaceutical Medicine, Vol. 20, Iss. 6, 2006-01 ,pp. : 355-359

Adis International

Access to resources Recommend Favorite

European Legislation on Herbal Medicines: A Look into the Future

By Calapai Gioacchino

Drug Safety, Vol. 31, Iss. 5, 2008-01 ,pp. : 428-431

Adis International

Access to resources Recommend Favorite

China to cut prices on over 2300 essential medicines

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 590, 2009-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite